Adjunctive therapies for AIDS dementia complex

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Uthman, Olalekan A ^a   Abdulmalik, Jubril O ^b  

^a Save the Youth Initiative   (Nigeria)

^b Federal Neuro Psychiatry Hospital Maiduguri   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTIRETROVIRUS AGENT; CPI 1189; GLYCERYL TRINITRATE; LEXIPAFANT; MEMANTINE; MINOCYCLINE; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; NIMODIPINE; PENTOXIFYLLINE; PEPTIDE T; PLACEBO; PREDNISONE; SELEGILINE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOCYTIC LEUKEMIA; BACKACHE; BACTERIAL PNEUMONIA; BIBLIOGRAPHIC DATABASE; BLEPHARITIS; BLOOD TOXICITY; CARDIOTOXICITY; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; COUGHING; DATA ANALYSIS; DATA BASE; DATA EXTRACTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMBASE; ENDOCRINE DISEASE; EXPERIMENTAL THERAPY; EXPERIMENTATION; FATIGUE; FEVER; GASTROESOPHAGEAL REFLUX; HEADACHE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INFLUENZA; INFORMATION PROCESSING; LEARNING TEST; LIVER FUNCTION; LOW DRUG DOSE; MEDLINE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; MOOD DISORDER; MORTALITY; NAUSEA; NEPHROLITHIASIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUTROPENIA; NOSE CONGESTION; ORGANIZATION; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PREVALENCE; PROTEINURIA; PSYCINFO; QUALITY CONTROL; QUALITY OF LIFE; RASH; RESEARCH SUBJECT; REVIEW; SCIENTIFIC LITERATURE; SIDE EFFECT; STRATIFICATION; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TOXICITY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 55049124708     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006496.pub2     Document Type: Review

References (63)

1. Clifford (high) 2002 {published data only} Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, et al.A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002;59(10):1568-73.
2. Clifford 2002 {published data only} Clifford DB, McArthur JC, Schifitto G, Kieburtz K, McDermott MP, Letendre S, et al.A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002;59(10):1568-73.
3. Dana (both) 1998 {published data only} A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1998;50(3):645-51.
4. Dana (thioctic) 1998 {published data only} A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1998;50(3):645-51.
5. Dana 1997 {published data only} Safety and tolerability of the antioxidant OPC-14117 in HIV-associated cognitive impairment. The Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1997;49(1):142-6.
6. Dana 1998 {published data only} * A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders. Neurology 1998;50(3):645-51.
7. Heseltine 1998 {published data only} Goodkin K, Vitiello B, Lyman WD, Asthana D, Atkinson JH, Heseltine PN, et al.Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. Journal of Neurovirology 2006;12(3):178-89.
8. Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, et al.Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Archives of Neurology 1998;55(1):41-51.
9. Navia (high) 1998 {published data only} Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al.A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998;51(1):221-8.
10. Navia 1998 {published data only} Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al.A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998;51(1):221-8.
11. Sacktor 2000 {published data only} * Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000;54(1):233-5.
12. Schiffito 1999 {published data only} Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, et al.Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 1999;53(2):391-6.
13. Schiffito 2006a {published data only} Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, et al.Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006;66(6):919-21.
14. Schiffito 2007a {published data only} Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al.Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007;21(4):1877-86.
15. Schiffito 2007b {published data only} Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al.A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69(13):1314-21.
16. Schifitto (high)2007 {published data only} Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al.A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007;69(13):1314-21.
17. Anonymous 1996 {published data only} * Analyses of peptide T efficacy on neuropsychological performance. AIDS Patient Care STDS 1996;10(1):52.
18. Brew 2007 {published data only} * Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, Brown S, et al.Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clinical Trials 2007;2(3):e13.
19. Bridge 1989 {published data only} * Bridge TP, Heseltine PN, Parker ES, Eaton E, Ingraham LJ, Gill M, et al.Improvement in AIDS patients on peptide T. Lancet 1989;2:226-7.
20. Bridge 1991 {published data only} * Bridge TP, Heseltine PN, Parker ES, Eaton EM, Ingraham LJ, McGrail ML, et al.Results of extended peptide T administration in AIDS and ARC patients. Psychopharmacology bulletin 1991;27:237-45.
21. Chang 2004 {published data only} * Chang L, Lee PL, Yiannoutsos CT, Ernst T, Marra CM, Richards T, et al.A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. NeuroImage 2004;23(4):1336-47.
22. Cysique 2006 {published data only} * Cysique LA, Maruff P, Brew BJ. Valproic acid is associated with cognitive decline in HIV-infected individuals: a clinical observational study. BMC neurology 2006;6:42.
23. Day 1992 {published data only} * Day JJ, Grant I, Atkinson JH, Brysk LT, McCutchan JA, Hesselink JR, et al.Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort. The Journal of Neuropsychiatry and Clinical Neurosciences 1992;4(1):15-20.
24. DiCenzo 2004 {published data only} * DiCenzo R, Peterson D, Cruttenden K, Morse G, Riggs G, Gelbard H, et al.Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrobial Agents and Chemotherapy 2004;48(11):4328-31.
25. Galgani 1997 {published data only} * Galgani S, Balestra P, Narciso P, Tozzi V, Sette P, Pau F, et al.Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits. AIDS 1997;11:1520-1.
26. Kosten 1997 {published data only} * Kosten TR, Rosen MI, McMahon TL, Bridge TP, O'Malley SS, Pearsall R. Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T. The American Journal of Drug and Alcohol Abuse 1997;23(4):543-53.
27. Lee 2003 {published data only} * Lee PL, Yiannoutsos CT, Ernst T, Chang L, Marra CM, Jarvik JG, et al.A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis. Journal of Magnetic Resonance Imaging 2003;17(6):625-33.
28. Polianova 2003 {published data only} * Polianova MT, Ruscetti FW, Pert CB, Tractenberg RE, Leoung G, et al.Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides 2003;24:1093-8.
29. Sacktor 2002 {published data only} * Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al.HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of Neurovirology 2002;8(2):136-42.
30. Schifitto 2001 {published data only} Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, et al.Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001;56(3):415-8.
31. Schifitto 2006b {published data only} * Schifitto G, Yiannoutsos CT, Simpson DM, Marra CM, Singer EJ, Kolson DL, et al.A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. Journal of Neurovirology 2006;12(4):328-31.
32. Schmitt 1988 {published data only} * Schmitt FA, Bigley JW, McKinnis R, Logue PE, Evans RW, Drucker JL. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. The New England Journal of Medicine 1988;319(24):1573-8.
33. Sidtis 1993 {published data only} * Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, et al.Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Annals of Neurology 1993;33(4):343-9.
34. Simpson 1996 {published data only} * Simpson DM, Dorfman D, Olney RK, McKinley G, Dobkin J, So Y, et al.Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 1996;47(5):1254-9.
35. Tozzi 1993 {published data only} * Tozzi V, Narciso P, Galgani S, Sette P, Balestra P, Gerace C, et al.Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993;7(5):683-92.
36. Villemagne 1996 {published data only} * Villemagne VL, Phillips RL, Liu X, Gilson SF, Dannals RF, Wong DF, et al.Peptide T and glucose metabolism in AIDS dementia complex. Journal of Nuclear Medicine 1996;37(7):1177-80.
37. Vitiello 1998 {unpublished data only} Vitiello B. Research on possible treatments of HIV-associated cognitive impairment. The XII International AIDS Conference; 1998 June 28 - July 3; Geneva, Switzerland. 1998:1148 (abstract no. 60804).
38. Minocycline 2006 {unpublished data only} Minocycline for the Treatment of Decreased Mental Function in HIV Infected Adults. www.clinicaltrials.gov/ct/show/NCT00361257?order=1 (accessed 28 May 2007).
39. Nimodipine 1999 {unpublished data only} Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1. www.clinicaltrials.gov/ct/show/NCT00000738?order=1 (accessed 28 May 2007).
40. AIDS institutes 2006 AIDS institutes. Cognitive disorders and HIV/AIDS: HIV - associated dementia and delirium. www.hivguidelines.org/ GuideLine.aspx?pageID=261&guideLineID=44&vType=txt (accessed 28 August 2006).
41. Birbeck 2005 Birbeck GL. Human immunodeficiency virus dementia patients in Africa: How many? Who cares? And where to from here?. Journal of Neurovirolology 2005;11 Suppl 3:30-3.
42. Chiesi 1996 Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, et al.Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1996;11(1):39-44.
43. Childs 1999 Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, et al.Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology 1999;52(3):607-13.
44. Dana 1996 Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology 1996;47(5):1247-53.
45. Edward 1987 Edward DD. Competition' cause of AIDS dementia? Science News Sept 1987. www.findarticles.com/p/articles/mi_m1200/is_v132/ ai_5197123 (accessed 23 July 2006).
46. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629-34.
47. Ghafouri 2006 Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006;3:28.
48. Gonzalez 2006 Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nature Reviews Immunology 2005;5(1):69- 81.
49. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
50. Higgins 2006 Higgins JPT, Green S, editors. Analysis and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 8. www.cochrane.org/resources/handbook/ hbook.htm (accessed 6th October 2006).
51. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42-6.
52. McArthur 2005 McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurology 2005;4(9):543-55.
53. Moher 1999 Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports ofmeta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896-900.
54. Mollace 2001 Mollace V, Nottet HS, Clayette P, Turco MC, Muscoli C, Salvemini D, et al.Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends in Neuroscience 2001;24(7):411-6.
55. Parnes 2006 Parnes RB. AIDS Dementia Complex. www.thirdage.com/ healthgate/files/43788.html (accessed 12 July 2006).
56. Price 1996 Price RW. Neurological complications of HIV infection. Lancet 1996;348(9025):445-52.
57. Ramsay 2007 Ramsay C. How do you include trials with more than two groups into a single meta-analysis?. www.epoc.uottawa.ca/FAQmultiplegroups2003. pdf (accessed 06 June 2007).
58. Review Manager 4.2 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
59. Sacktor 1997 Sacktor N, McArthur J. Prospects for therapy of HIV-associated neurologic diseases. Journal of Neurovirology 1997;3(2):89-101.
60. Selnes 1991 Selnes OA, Jacobson L, Machado AM, Becker JT, Wesch J, Miller EN. Normative data for a brief neuropsychological screening battery. Multicenter AIDS Cohort Study. Perceptual and Motor Skills 1991;73(2):539-50.
61. Stern 2001 Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, et al.Factors associated with incident human immunodeficiency virus-dementia. Archives of Neurology 2001;58(3):473-9.
62. Turchan 2003 Turchan J, Sacktor N, Wojna V, Conant K, Nath A. Neuroprotective therapy for HIV dementia. Current HIV Research 2003;1:373-83.
63. Zink 2005 Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, et al.Neuroprotective and anti-human immunodeficiency virus activity of minocycline. Journal of the American Medical Association 2005;293(16):2003-11.